WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406361
Description: NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer). Cells were treated with increasing concentrations of TM or TP +/- NU1085 (10 microM) for 72 h.
MedKoo Cat#: 406361
Chemical Formula: C14H11N3O2
Exact Mass: 253.08513
Molecular Weight: 253.26
Elemental Analysis: C, 66.40; H, 4.38; N, 16.59; O, 12.63
Synonym: NU1085; NU-1085; NU 1085.
IUPAC/Chemical Name: 2-(4-hydroxyphenyl)-1H-benzo[d]imidazole-7-carboxamide
InChi Key: KOUGHMOSYJCJLE-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H11N3O2/c15-13(19)10-2-1-3-11-12(10)17-14(16-11)8-4-6-9(18)7-5-8/h1-7,18H,(H2,15,19)(H,16,17)
SMILES Code: O=C(C1=C2NC(C3=CC=C(O)C=C3)=NC2=CC=C1)N
1: Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000 Jul;6(7):2860-7. PubMed PMID: 10914735.